Biography:
Buwei Wang graduated from Beijing University of Chinese Medicine with master’s degree. Her present position is Medical Manager in Sironax, a biotechnology company that is emerging leader in the discovery and development of transformational therapies that address the root cause of age-related degenerative disease. She oversees the clinical trials of RIPK1 inhibitors that are currently under development from Sironax.
Title : Safety, pharmacokinetics and target engagement of a novel brain penetrant RIPK1 inhibitor (SIR9900) in healthy volunteers with therapeutic potential for neurodegenerative diseases